EPH Stats & Data
CCOC(=O)C(N1CCCCC1)c1ccccc1AGSKYKDXQOBAPX-UHFFFAOYSA-NInteraction Warnings
The neurotoxic effects of MDMA may be increased when combined with other stimulants.
This combination may increase strain on the heart.
History & Culture
Ethylphenidate emerged on the recreational drug market around 2010-2011 and gained increasing popularity over the subsequent years. It became primarily distributed as a research chemical through online vendors, exploiting its grey-area legal status in various jurisdictions during this period. The substance was also stocked by head shops in major cities across the United Kingdom and elsewhere, where it was sometimes sold both as a standalone product and as a component of blended preparations. One notable example was certain formulations marketed as "GoGaine," which combined ethylphenidate with other substances including MPA, lidocaine, and mannitol. An interesting aspect of ethylphenidate's pharmacological history relates to its endogenous formation within the human body. Small quantities of ethylphenidate can be produced through hepatic transesterification when ethanol and methylphenidate are co-ingested. This metabolic pathway parallels the formation of cocaethylene when cocaine and alcohol are consumed together. However, only a small percentage of consumed methylphenidate undergoes this conversion, meaning pharmacologically significant concentrations with measurable physiological effects would not typically be produced through this mechanism under normal circumstances. The phenomenon is most likely to occur in scenarios involving large quantities of both substances, such as in cases of non-medical use or overdose.
Subjective Effect Notes
physical: The physical effects of ethylphenidate can be broken down into several components which progressively intensify proportional to dosage.
cognitive: The cognitive effects of ethylphenidate can be broken down into several components which progressively intensify proportional to dosage. The general head space of ethylphenidate is described by many as one of extreme mental stimulation, increased focus, and powerful euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate dosages, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Effect Profile
Curated + 51 ReportsStrong stimulation, euphoria, focus, and anxiety/jitters
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 51 experience reports (51 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 9
Adverse Effects 11
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Threshold (n=17) |
|---|---|
| Stimulation | 82.4% |
| Euphoria | 76.5% |
| Anxiety | 58.8% |
| Music Enhancement | 47.1% |
| Empathy | 41.2% |
| Focus Enhancement | 41.2% |
| Jaw Clenching | 35.3% |
| Confusion | 29.4% |
| Color Enhancement | 23.5% |
| Introspection | 17.6% |
| Sweating | 17.6% |
| Pupil Dilation | 17.6% |
| Sedation | 17.6% |
| Auditory Effects | 17.6% |
| Nausea | 17.6% |
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 51 experience reports.
Limited tier coverage — most reports fall within the Threshold range. Effects at other dose levels may not be represented.
| Effect | Threshold (n=17) | |
|---|---|---|
| stimulation | ||
| euphoria | ||
| anxiety | ||
| music enhancement | ||
| empathy | ||
| focus enhancement | ||
| jaw clenching | ||
| confusion | ||
| color enhancement | ||
| introspection | ||
| sweating | ||
| pupil dilation | ||
| sedation | ||
| auditory effects | ||
| nausea | ||
| appetite suppression | ||
| ego dissolution | ||
| tactile enhancement | ||
| increased heart rate |
Dosage Distribution
Dose distribution from experience reports
Real-World Dose Distribution
62K DosesFrom 113 individual dose entries
Oral (n=31)
Rectal (n=10)
Insufflated (n=55)
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Insufflated
Oral
Redose Patterns
Redosing behavior across 49 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Australia | Controlled (analogue provisions) | Australian state and federal legislation contains provisions covering analogues of controlled drugs. Ethylphenidate falls under these provisions as an analogue of methylphenidate. |
| Austria | Illegal (NPSG) | Prohibited since January 1, 2012 under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). |
| Canada | Schedule III (CDSA) | Listed on the Controlled Drugs and Substances Act in Schedule III as of May 5, 2017. Previously unscheduled with no analog law covering it. |
| Denmark | Illegal | Controlled substance as of February 1, 2013. |
| Germany | Anlage II BtMG | Controlled under Anlage II of the Betäubungsmittelgesetz (Narcotics Act) as of July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license is prohibited. |
| Jersey | Illegal | Controlled under the Misuse of Drugs (Jersey) Law 1978. |
| Netherlands | Lijst I (Opiumwet) | Listed in Lijst I of the Opiumwet (Opium Act) as of April 27, 2018. |
| Norway | Unscheduled | Not specifically listed as controlled under the Forskrift om narkotika (narcotics regulation). Despite structural similarity to methylphenidate, Norwegian law does not automatically control ethylphenidate as an analogue. |
| Sweden | Illegal (Appendix 1) | Listed in Appendix 1 of Swedish drug control regulations as of December 15, 2012, making it illegal for most purposes. |
| Switzerland | Controlled (Verzeichnis D) | Specifically named as a controlled substance under Verzeichnis D of Swiss drug regulations. |
| United Kingdom | Class B | Initially placed under emergency control as a Temporary Class Drug in April 2015 along with other phenidates, restricting sale and manufacture. Subsequently classified as a Class B drug on May 31, 2017, making possession, production, and supply illegal. |
| United States | Unscheduled (federally) | Not explicitly scheduled at the federal level. However, as a structural analogue of methylphenidate (Schedule II), it could potentially be prosecuted under the Federal Analogue Act if sold for human consumption or possessed with intent to ingest. Specifically controlled in Utah along with its analogues, homologs, and synthetic equivalents. |